Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
AI Summary
Optimi Health has introduced new standardized microdose psilocybin products, offering precise 1mg and 2mg formulations tailored for clinical research. These additions extend Optimi's existing range that includes a 5mg psilocybin product already commercially available for treatment-resistant depression in Australia. This development is significant as it provides researchers with validated, consistent doses crucial for controlled studies, potentially accelerating advancements in psychedelic medicine research.
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.